Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma

Yun Yen, Samuel So, Michal Rose, M. Wasif Saif, Edward Chu, Shwu Huey Liu, Angeline Foo, Zaoli Jiang, Tahmun Su, Yung Chi Cheng

研究成果: 雜誌貢獻文章同行評審

56 引文 斯高帕斯(Scopus)

摘要

PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

原文英語
頁(從 - 到)4083-4092
頁數10
期刊Anticancer Research
29
發行號10
出版狀態已發佈 - 十月 2009

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma」主題。共同形成了獨特的指紋。

引用此